Basel Medical Group Ltd (BMGL) AI Stock Analysis
BMGL AI stock analysis summary
AI ResearchBasel Medical Group Ltd (BMGL) is a Singapore-based healthcare provider specializing in orthopedic, neurosurgical, and general medical services. Although revenue grew 12.6% in FY2025 to $11.3M, net income swung to -$12.1M with an operating margin of -19.3%. Trailing twelve month revenue reached $14.7M with quarterly revenue growth of 67.1% as of March 31, 2026.
- Market cap
- $6.2M
- Revenue (TTM)
- $14.7M
- P/E
- —
- 1Y return
- -78.5% S&P 500 16.8%
- Avg. target
- —
Bull case
- Quarterly revenue grew 67.1% year-over-year in the period ending March 31, 2026.
- Gross margin remained strong across reporting periods, standing at 77.7% in FY2025.
- The stock trades at a price-to-sales multiple of 0.4x, well below the median of its US-listed Healthcare peers of 4.1x.
Bear case
- Net income dropped to -$12.1M in FY2025, compared to positive net income of $2.1M in FY2024.
- Free cash flow turned negative at -$4.4M in FY2025, down from $2.5M in FY2024.
- Total debt of $9.9M significantly exceeds cash and short-term investments of $1.3M as of March 31, 2026.
What Basel Medical does
Basel Medical Group Ltd provides healthcare services in Singapore. The company offers general and subspecialized orthopedic services, including trauma and sports medicine services such as knee and hip replacements, sports surgery, spine surgery, foot and ankle surgery, and minimally invasive orthopedic procedures. It also provides neurosurgical treatments. In addition, its offerings include health screening, mental health, woman's health, and general practice services. The company's scope covers medical consultation, diagnosis, and both medical and surgical treatments. Incorporated in 2023, the organization is headquartered in Singapore and employs 82 people.
Growth and profitability
From FY2022 to FY2025, revenue grew at a 3-year CAGR of 2.0%, moving from $10.7M in FY2022 to $9.7M in FY2023, $10.1M in FY2024, and $11.3M in FY2025. Gross margin has remained consistent, recording 79.6% in FY2022, 75.9% in FY2023, 77.6% in FY2024, and 77.7% in FY2025. Profitability contracted sharply in FY2025, as operating margin stood at -19.3% and net income totaled -$12.1M, compared to net income of $2.1M in FY2024. Operating cash flow also turned negative at -$4.3M in FY2025. Over the trailing twelve months ended March 31, 2026, revenue was $14.7M with quarterly revenue growth of 67.1% year-over-year, while profit margin was -68.2% and EPS was -$4.98.
Balance sheet and cash flow
As of March 31, 2026, Basel Medical Group Ltd held $1.3M in cash and short-term investments alongside total debt of $9.9M, leaving net debt at $8.5M. Total assets stood at $20.1M against shareholders' equity of $6.3M, resulting in a debt-to-equity ratio of 1.57 and a current ratio of 1.88. For FY2025, free cash flow was -$4.4M, while capital expenditures totaled $54,760.
Valuation and performance
At the last close of $3.95 on October 16, 2026, Basel Medical Group Ltd had a market cap of $6.2M and an enterprise value of $12.5M. The stock trades at a price-to-sales multiple of 0.4x and an enterprise value-to-revenue multiple of 1.1x, below the median of its US-listed Healthcare peers price-to-sales of 4.1x. Its EV-to-EBITDA ratio of 38.9x sits above the peer median of 12.0x, alongside a price-to-book ratio of 1.3x. Over the past year, the stock fell 78.5%, trailing the S&P 500 return of 16.8%, and closed 40.5% below its 200-day average.
What analysts expect
Basel Medical Group Ltd does not have published consensus analyst ratings, earnings estimates, or price targets following its IPO in 2025. As of October 16, 2026, the stock closed at $3.95, between its 52-week low of $2.56 and 52-week high of $21.72. The company's ownership profile reflects insider ownership of 11.2%, institutional ownership of 0.0%, and a short interest of 1.6% of the float.
Key risks and what to watch
- Net debt of $8.5M and a debt-to-equity ratio of 1.57 create balance sheet leverage after operating cash flow fell to -$4.3M in FY2025.
- Operating margin declined to -19.3% in FY2025 and sat at -32.8% on a trailing twelve month basis.
- The stock price fell 78.5% over the past year and remains 40.5% below its 200-day moving average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this BMGL AI stock analysis
This page is an AI-written research summary of Basel Medical Group Ltd (BMGL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: BMGL income statement, BMGL balance sheet, BMGL key metrics, BMGL chart. See the BMGL stock overview for the latest quote and news.
BMGL AI stock analysis FAQ
What was Basel Medical Group Ltd's revenue growth in FY2025?
Revenue grew 12.6% to $11.3M in FY2025, up from $10.1M in FY2024.
Is BMGL profitable?
No, Basel Medical Group Ltd reported net income of -$12.1M and an operating margin of -19.3% in FY2025, with trailing twelve month EPS of -$4.98.
How much cash and debt does Basel Medical Group Ltd have?
As of March 31, 2026, the company held $1.3M in cash and short-term investments and $9.9M in total debt, resulting in net debt of $8.5M.
Does BMGL pay a dividend?
Basel Medical Group Ltd does not pay a dividend.
How has BMGL stock performed over the past year?
Over the past year through October 16, 2026, BMGL shares declined 78.5%, compared to a 16.8% return for the S&P 500.